Towards a molecular characterisation of pathological pathways.


The dominant conceptual reductionism in drug discovery has resulted in many promising drug candidates to fail during the last clinical phases, mainly due to a lack of knowledge about the patho-physiological pathways they are acting on. Consequently, to increase the revenues of the drug discovery process, we need to improve our understanding of the molecular… (More)
DOI: 10.1016/j.febslet.2008.02.014